Failed remyelination of the nonhuman primate optic nerve leads to axon degeneration, retinal damages, and visual dysfunction.
demyelination
nonhuman primate
optic nerve
visual dysfunction
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
08 03 2022
08 03 2022
Historique:
entrez:
2
3
2022
pubmed:
3
3
2022
medline:
22
3
2022
Statut:
ppublish
Résumé
White matter disorders of the central nervous system (CNS), such as multiple sclerosis (MS), lead to failure of nerve conduction and long-lasting neurological disabilities affecting a variety of sensory and motor systems, including vision. While most disease-modifying therapies target the immune and inflammatory response, the promotion of remyelination has become a new therapeutic avenue to prevent neuronal degeneration and promote recovery. Most of these strategies have been developed in short-lived rodent models of demyelination, which spontaneously repair and do not reflect the size, organization, and biology of the human CNS. Thus, well-defined nonhuman primate models are required to efficiently advance therapeutic approaches for patients. Here, we followed the consequence of long-term toxin-induced demyelination of the macaque optic nerve on remyelination and axon preservation, as well as its impact on visual functions. Findings from oculomotor behavior, ophthalmic examination, electrophysiology, and retinal imaging indicate visual impairment involving the optic nerve and retina. These visual dysfunctions fully correlated at the anatomical level, with sustained optic nerve demyelination, axonal degeneration, and alterations of the inner retinal layers. This nonhuman primate model of chronic optic nerve demyelination associated with axonal degeneration and visual dysfunction, recapitulates several key features of MS lesions and should be instrumental in providing the missing link to translate emerging repair promyelinating/neuroprotective therapies to the clinic for myelin disorders, such as MS.
Identifiants
pubmed: 35235463
doi: 10.1073/pnas.2115973119
pmc: PMC8916013
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2115973119Subventions
Organisme : NINDS NIH HHS
ID : R01 NS105741
Pays : United States
Références
PLoS One. 2016 Jun 03;11(6):e0156927
pubmed: 27257864
ACS Pharmacol Transl Sci. 2019 Nov 14;2(6):372-386
pubmed: 32259071
J Clin Invest. 2019 Feb 1;129(2):863-874
pubmed: 30667376
J Neurol. 2016 Jul;263(7):1323-31
pubmed: 27142714
Brain. 2008 Jul;131(Pt 7):1749-58
pubmed: 18515322
Acta Neuropathol. 1981;53(2):93-8
pubmed: 7211208
Invest Ophthalmol Vis Sci. 2016 Sep 01;57(11):4859-4868
pubmed: 27654412
Nat Commun. 2019 Aug 29;10(1):3887
pubmed: 31467299
Ann Neurol. 2015 Mar;77(3):517-28
pubmed: 25559267
Elife. 2018 Sep 11;7:
pubmed: 30204081
PLoS One. 2014 Aug 28;9(8):e102546
pubmed: 25166273
J Neurocytol. 1974 Dec;3(6):659-75
pubmed: 4461770
Acta Neuropathol. 2018 Apr;135(4):511-528
pubmed: 29441412
J Neurol. 2005 Nov;252 Suppl 5:v25-9
pubmed: 16254698
PLoS One. 2020 Jun 8;15(6):e0233980
pubmed: 32511247
Neurol Neuroimmunol Neuroinflamm. 2018 Dec 21;6(2):e533
pubmed: 30697584
Brain Res. 2010 Sep 10;1351:50-56
pubmed: 20637745
Lancet. 2017 Dec 2;390(10111):2481-2489
pubmed: 29029896
J Neurosci. 2013 Feb 20;33(8):3514-25
pubmed: 23426679
Brain. 2012 Feb;135(Pt 2):521-33
pubmed: 22006982
J Neurosci. 1998 Jan 15;18(2):601-9
pubmed: 9425002
Brain. 2011 Apr;134(Pt 4):1168-83
pubmed: 21459827
Nature. 1978 Sep 28;275(5678):326-7
pubmed: 692713
J Neuroinflammation. 2019 Nov 4;16(1):203
pubmed: 31684959
Brain. 2017 Apr 1;140(4):967-980
pubmed: 28334918
Acta Neuropathol. 2020 Nov;140(5):715-736
pubmed: 32894330
PLoS One. 2013 Aug 19;8(8):e71855
pubmed: 23977164
Nat Neurosci. 2020 Jul;23(7):819-831
pubmed: 32424285
J Cell Commun Signal. 2017 Jun;11(2):191-192
pubmed: 28493107
Nature. 2019 Feb;566(7745):543-547
pubmed: 30747918
Nat Rev Neurosci. 2008 Nov;9(11):839-55
pubmed: 18931697
Glia. 1998 Feb;22(2):161-70
pubmed: 9537836
Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2243-E2252
pubmed: 28246330
Doc Ophthalmol. 2006 Sep;113(2):123-32
pubmed: 16972082
Acta Neuropathol. 2020 Sep;140(3):359-375
pubmed: 32710244
Semin Cell Dev Biol. 2021 Aug;116:53-61
pubmed: 33082116
N Engl J Med. 2002 Jan 17;346(3):165-73
pubmed: 11796850
Brain Pathol. 2005 Jul;15(3):198-207
pubmed: 16196386
Nat Rev Neurosci. 2017 Nov 16;18(12):753-769
pubmed: 29142295
Sci Adv. 2020 Dec 4;6(49):
pubmed: 33277253
Electroencephalogr Clin Neurophysiol. 1989 Jan-Feb;74(1):1-10
pubmed: 2463143
Annu Rev Neurosci. 2008;31:247-69
pubmed: 18558855
Lancet Neurol. 2006 Oct;5(10):853-63
pubmed: 16987732
Invest Ophthalmol Vis Sci. 2011 Aug 29;52(9):6911-8
pubmed: 21791585
J Neurol Sci. 2001 Jul 15;188(1-2):37-41
pubmed: 11489283
Neurotherapeutics. 2017 Oct;14(4):894-904
pubmed: 28948533
Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11807-E11816
pubmed: 30487224
Nat Neurosci. 2019 Jul;22(7):1046-1052
pubmed: 31182869
Brain. 2002 Oct;125(Pt 10):2202-12
pubmed: 12244078
Prog Neurobiol. 2011 Jan;93(1):1-12
pubmed: 20946934
J Mol Neurosci. 2012 Sep;48(1):77-85
pubmed: 22552714
Brain. 2001 Mar;124(Pt 3):468-79
pubmed: 11222447
Proc Natl Acad Sci U S A. 2019 Dec 23;:
pubmed: 31871177
Proc Natl Acad Sci U S A. 2019 Dec 16;:
pubmed: 31843913
J Neurol. 2016 Apr;263(4):695-702
pubmed: 26860093
Glia. 2020 Apr;68(4):705-720
pubmed: 31633852
Brain. 2010 Jun;133(Pt 6):1591-601
pubmed: 20410146
Brain Res. 1980 Mar 31;186(2):301-13
pubmed: 7357456
Clin Exp Optom. 2012 Mar;95(2):223-8
pubmed: 22329676